| Number of patients . | 43 . |
|---|---|
| Median age at diagnosis, years (range) | 64 (36 to 77) |
| Sex, N (%) | |
| Male | 24 (56) |
| Female | 19 (44) |
| Race, N (%) | |
| Asian | 1 (2.5) |
| Black or African American | 1 (2.5) |
| White | 41 (95) |
| ECOG, N (%) | |
| 0 | 18 (42) |
| 1 | 23 (53) |
| Not available | 2 (5) |
| Baseline hypertension, N (%) | |
| Yes | 21 (49) |
| No | 22 (51) |
| Patients with increased baseline chromogranin A (>95 U/mL) | 37 |
| Baseline chromogranin A, ng/mL | |
| Median | 522 |
| Range | 28-12 860 |
| Histologic grade of extra-pulmonary/thymic NET cohort, N (%) | |
| Low (grade 1) | 8 (18) |
| Intermediate (grade 2) | 7 (16) |
| High (grade 3) | 3 (7) |
| Unknown | 12 (28) |
| Histologic variants of pulmonary/thymic cohort, N (%) | |
| Typical | 1 (2) |
| Atypical | 10 (23) |
| Large cell | 1 (2) |
| Unknown | 2 (4) |
| Primary tumor location, N (%) | |
| Small intestine | 20 (46) |
| Lung | 10 (23) |
| Thymus | 3 (7) |
| Rectum | 1 (2) |
| Kidney | 1 (2) |
| Unknown | 8 (18) |
| Prior therapy, N (%) | |
| Somatostatin analog | 35 (81%) |
| Chemotherapy | 13 (30) |
| Interferon | 1 (2) |
| Everolimus | 24 (56) |
| VEGF pathway inhibitor | |
| Cabozantinib | 5 (12) |
| Axitinib | 1 (2) |
| Sunitinib | 1 (2) |
| Ziv-Aflibercept | 3 (7) |
| Sorafenib | 1 (2) |
| Investigational therapy* | 3 (7) |
| Liver directed therapy | 1 (2) |
| Radiation therapy | 12 (28) |
| Peptide radionuclide receptor therapy | 3 (7) |
| Number of patients . | 43 . |
|---|---|
| Median age at diagnosis, years (range) | 64 (36 to 77) |
| Sex, N (%) | |
| Male | 24 (56) |
| Female | 19 (44) |
| Race, N (%) | |
| Asian | 1 (2.5) |
| Black or African American | 1 (2.5) |
| White | 41 (95) |
| ECOG, N (%) | |
| 0 | 18 (42) |
| 1 | 23 (53) |
| Not available | 2 (5) |
| Baseline hypertension, N (%) | |
| Yes | 21 (49) |
| No | 22 (51) |
| Patients with increased baseline chromogranin A (>95 U/mL) | 37 |
| Baseline chromogranin A, ng/mL | |
| Median | 522 |
| Range | 28-12 860 |
| Histologic grade of extra-pulmonary/thymic NET cohort, N (%) | |
| Low (grade 1) | 8 (18) |
| Intermediate (grade 2) | 7 (16) |
| High (grade 3) | 3 (7) |
| Unknown | 12 (28) |
| Histologic variants of pulmonary/thymic cohort, N (%) | |
| Typical | 1 (2) |
| Atypical | 10 (23) |
| Large cell | 1 (2) |
| Unknown | 2 (4) |
| Primary tumor location, N (%) | |
| Small intestine | 20 (46) |
| Lung | 10 (23) |
| Thymus | 3 (7) |
| Rectum | 1 (2) |
| Kidney | 1 (2) |
| Unknown | 8 (18) |
| Prior therapy, N (%) | |
| Somatostatin analog | 35 (81%) |
| Chemotherapy | 13 (30) |
| Interferon | 1 (2) |
| Everolimus | 24 (56) |
| VEGF pathway inhibitor | |
| Cabozantinib | 5 (12) |
| Axitinib | 1 (2) |
| Sunitinib | 1 (2) |
| Ziv-Aflibercept | 3 (7) |
| Sorafenib | 1 (2) |
| Investigational therapy* | 3 (7) |
| Liver directed therapy | 1 (2) |
| Radiation therapy | 12 (28) |
| Peptide radionuclide receptor therapy | 3 (7) |
*Investigational therapies included pembrolizumab, 2-,methoxyestradiol, VB-111(ofranergene obadenovec).
| Number of patients . | 43 . |
|---|---|
| Median age at diagnosis, years (range) | 64 (36 to 77) |
| Sex, N (%) | |
| Male | 24 (56) |
| Female | 19 (44) |
| Race, N (%) | |
| Asian | 1 (2.5) |
| Black or African American | 1 (2.5) |
| White | 41 (95) |
| ECOG, N (%) | |
| 0 | 18 (42) |
| 1 | 23 (53) |
| Not available | 2 (5) |
| Baseline hypertension, N (%) | |
| Yes | 21 (49) |
| No | 22 (51) |
| Patients with increased baseline chromogranin A (>95 U/mL) | 37 |
| Baseline chromogranin A, ng/mL | |
| Median | 522 |
| Range | 28-12 860 |
| Histologic grade of extra-pulmonary/thymic NET cohort, N (%) | |
| Low (grade 1) | 8 (18) |
| Intermediate (grade 2) | 7 (16) |
| High (grade 3) | 3 (7) |
| Unknown | 12 (28) |
| Histologic variants of pulmonary/thymic cohort, N (%) | |
| Typical | 1 (2) |
| Atypical | 10 (23) |
| Large cell | 1 (2) |
| Unknown | 2 (4) |
| Primary tumor location, N (%) | |
| Small intestine | 20 (46) |
| Lung | 10 (23) |
| Thymus | 3 (7) |
| Rectum | 1 (2) |
| Kidney | 1 (2) |
| Unknown | 8 (18) |
| Prior therapy, N (%) | |
| Somatostatin analog | 35 (81%) |
| Chemotherapy | 13 (30) |
| Interferon | 1 (2) |
| Everolimus | 24 (56) |
| VEGF pathway inhibitor | |
| Cabozantinib | 5 (12) |
| Axitinib | 1 (2) |
| Sunitinib | 1 (2) |
| Ziv-Aflibercept | 3 (7) |
| Sorafenib | 1 (2) |
| Investigational therapy* | 3 (7) |
| Liver directed therapy | 1 (2) |
| Radiation therapy | 12 (28) |
| Peptide radionuclide receptor therapy | 3 (7) |
| Number of patients . | 43 . |
|---|---|
| Median age at diagnosis, years (range) | 64 (36 to 77) |
| Sex, N (%) | |
| Male | 24 (56) |
| Female | 19 (44) |
| Race, N (%) | |
| Asian | 1 (2.5) |
| Black or African American | 1 (2.5) |
| White | 41 (95) |
| ECOG, N (%) | |
| 0 | 18 (42) |
| 1 | 23 (53) |
| Not available | 2 (5) |
| Baseline hypertension, N (%) | |
| Yes | 21 (49) |
| No | 22 (51) |
| Patients with increased baseline chromogranin A (>95 U/mL) | 37 |
| Baseline chromogranin A, ng/mL | |
| Median | 522 |
| Range | 28-12 860 |
| Histologic grade of extra-pulmonary/thymic NET cohort, N (%) | |
| Low (grade 1) | 8 (18) |
| Intermediate (grade 2) | 7 (16) |
| High (grade 3) | 3 (7) |
| Unknown | 12 (28) |
| Histologic variants of pulmonary/thymic cohort, N (%) | |
| Typical | 1 (2) |
| Atypical | 10 (23) |
| Large cell | 1 (2) |
| Unknown | 2 (4) |
| Primary tumor location, N (%) | |
| Small intestine | 20 (46) |
| Lung | 10 (23) |
| Thymus | 3 (7) |
| Rectum | 1 (2) |
| Kidney | 1 (2) |
| Unknown | 8 (18) |
| Prior therapy, N (%) | |
| Somatostatin analog | 35 (81%) |
| Chemotherapy | 13 (30) |
| Interferon | 1 (2) |
| Everolimus | 24 (56) |
| VEGF pathway inhibitor | |
| Cabozantinib | 5 (12) |
| Axitinib | 1 (2) |
| Sunitinib | 1 (2) |
| Ziv-Aflibercept | 3 (7) |
| Sorafenib | 1 (2) |
| Investigational therapy* | 3 (7) |
| Liver directed therapy | 1 (2) |
| Radiation therapy | 12 (28) |
| Peptide radionuclide receptor therapy | 3 (7) |
*Investigational therapies included pembrolizumab, 2-,methoxyestradiol, VB-111(ofranergene obadenovec).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
